Figure 1.
PRISMA Flow diagram.
Table 1.
Table 1. Clinical Setting and Hydration Protocols of Included Trials.
Table 2.
Population Characteristics of Included Trials.
Table 3.
Quality Assessment of Included Trials.
Figure 2.
Forest plot of randomized trials meeting inclusion criteria.
Size of data markers indicates the weight of the trial. Trials are ordered by year.
Figure 3.
Funnel Plot showing the Peto log odds ratio on the x-axis and the standard error on the y-axis.
There is no obvious asymmetry to suggest missing unpublished trials.
Figure 4.
Forest plot including only trials with a prespecified protocol for oral volume expansion showing resolution of heterogeneity.
Figure 5.
Metaregression of the average total contrast dose administered on the X-axis against the log Peto odds ratio on the Y-axis.
This shows that there is a significant trend towards lower CI-AKI with intravenous expansion compared to oral expansion as the contrast dose increases.
Figure 6.
Metaregression of the proportion of patients with diabetes in a trial on the X-axis against the log Peto odds ratio on the Y-axis.
This shows that there is a significant trend to greater benefit with oral volume expansion in trials with a higher proportion of diabetic patients.